BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...

Eli Lilly and Nvidia are launching a joint artificial intelligence lab in South San Francisco with 70 people to speed up drug ...

Ozempic isn’t the only drug that mimics the natural GLP-1 hormone, so users feel fuller for longer and eat less. There’s also ...

Eli Lilly is already one of the most innovative companies in the pharmaceutical industry. Over the past five years, it has ...

Public Citizen filed a lawsuit against the Trump administration in the U.S. District Court for the District of Columbia ...

Eli Lilly (NYSE: LLY) announced a global research collaboration with Seamless Therapeutics to develop programmable gene ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...

Patients know about nausea and vomiting. Now, lawsuits are raising concerns about vision loss.

By Mariam Sunny and Bhanvi Satija Jan 28 (Reuters) - U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion ...

Some patients have pointed to severe undisclosed side effects, including blindness, loss of brain function and organ damage.

While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP ...

Repertoire Immune Medicines partners with Eli Lilly to develop tolerizing therapies for autoimmune diseases, receiving $85 ...